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summary
Chronic pain has been identified as an important issue related to various rheumatic diseases. At the time of a 
major government spending review, it is appropriate to discuss the pain characterising rheumatic diseases and 
its related costs. It is clearly essential for healthcare authorities to rationalise their policies on the basis of the in-
creasing expectations of the users of healthcare services while simultaneously balancing their books. There are 
few published studies concerning the costs of pain of any kind, and the same is true of the costs of the chronic 
pain associated with diseases such as rheumatoid arthritis, osteoarthritis, and fibromyalgia. 
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n	 INTRODUCTION
Chronic pain (CP) is a frequent health-care problem worldwide and the main 
reason for patients seeking medical advice 
(1). It affects a large proportion of the in-
habitants of the USA, where its prevalence 
is much higher than that of other conditions 
having a major social impact: back pain is 
the main cause of disability among Ameri-
cans aged <45 years, and the latest statis-
tics show that it affects about 26 million 
aged 20-64 years (2).
About 10 million people in the UK suf-
fer from various forms of pain that have 
serious consequences on their quality of 
life and working activities. The National 
Rheumatoid Arthritis Society estimates that 
about 9.4 million working days are lost be-
cause of rheumatoid arthritis (RA), and 4.9 
million because of back pain (3).
Pain in rheumatic disease (RD) (particu-
larly chronic pain) has been identified as 
an important issue by the National Health 
Plan 2011-2013 of the Italian Ministry of 
Health (4, 5). It is considered a disease that 
has its own nosographic dignity. Further-
more pain measurements and further infor-
mation required by medical and healthcare 
personnel in order to improve the patients’ 
quality of life also involves ethical aspects 
that have not yet been considered (6). This 
is also highlighted by other important bod-
ies, such as the International Association 
for the Study of Pain (IASP), the European 
Federation of IASP Chapters (EFIC®), the 
Italian Association for the Study of pain 
(AISD), and the Paolo Procacci Founda-
tion (FPP). 
The World Health Organization (WHO) is 
developing a new International Classifica-
tion of Diseases (ICD-11) to be published 
in 2015 that will include a section entirely 
dedicated to pain as a nosographic element 
in itself and not only related to organ and 
system pathologies (current code 338). 
In Italy, Law No. 38 entitled Provisions for 
access to palliative treatments and pain 
therapy was approved on 15 March 2010 
(7), and amended Presidential Decree No. 
309 of 9 October 1990 (Text for the laws 
regulating the use of narcotic and psycho-
tropic substances) by further simplifying 
the regulations governing the prescription 
of drugs for the treatment of pain. Article 9 
of Law No. 38/2010 states that the Minis-
try will provide the Regions with elements 
for evaluating the trends in the prescription 
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of drugs for the treatment of pain, particu-
larly opioid drugs.
This law is highly innovative because it 
guarantees the access of patients to pal-
liative therapies and pain treatment in au-
thorized centers, ensuring respect for their 
dignity, autonomy and healthcare needs; 
equal access to care; the quality of the care 
itself; and appropriate treatments for spe-
cial cases. 
In general, the most important features of 
the legislation are: 
1. Pain recording from the clinical re-
cords;
2. National assistance for palliative drugs 
and pain treatments;
3. Simplification of the procedures to have 
access to the drugs used to treat pain; 
4. Training for medical and healthcare 
personnel. 
The law has also been acknowledged out-
side Italy, as indicated at the Third Interna-
tional Symposium - Societal Impact of Pain 
SIP 2012 and in the publication entitled 
Pain proposal - Improving the Current and 
Future Management of CP (8, 9).
As is happening in other economically 
stronger European and non-European 
countries, in Italy the National Health Ser-
vice is going through a major economic 
and financial crisis that is mainly due to a 
reduction in funding. It was established in 
1978 during a period of relative economic 
prosperity, inspired by the principle of soli-
darity, and mainly funded by the popula-
tion, but it is now struggling to find sustain-
able means of balancing the books, reduc-
ing the national budget, and reorganizing 
its structure without affecting the princi-
ples that inspired its creation (10). 
As in the rest of the world, RDs in Italy 
have a social impact that is greater than that 
of many other diseases because of the high 
costs involved, which can be divided into 
three main groups: 
1. Direct costs, such as the cost of drugs, 
diagnostic examinations, care and hos-
pitalization, and also private consulta-
tions; 
2. Indirect costs, such as lost work days or 
unemployment due to the disease, ter-
mination of contracts given the impos-
sibility of working, transport to hospital 
and/or visits in private practices (and 
the possible lost work day by anyone 
accompanying the patient), pushing 
patients to work even when their job 
performance is serious affected because 
their physical condition;
3. Intangible costs arising for instance 
from significant changes in the quality 
of life and social habits (e.g. those re-
lating to interpersonal relationships, or 
severe difficulties in pursuing a hobby). 
The first two groups have measurable pa-
rameters, although their calculation is not 
easy because of the many variables in-
volved, whereas the costs in the third group 
can hardly be measured at all, and remain 
a matter of discussion between health au-
thorities and patients. 
The negative impact of RDs on the pa-
tients’ quality of life and working activity 
has been examined in a recent study con-
ducted in six European countries (Belgium, 
Bulgaria, Ireland, Portugal, Spain and UK) 
(11).
n	 COSTS OF PAIN  
 IN OSTEOARTHRITIS
Pain is the main symptom of RDs: the pain 
related to osteoarthritis (OA) affects 10% 
of the Italian population with a prevalence 
of 7,129,842 cases, in particular in female 
sex (12). 
Colombo et al. investigated the cost of 
acute and chronic pain in a prospective, 
observational study of the costs and the 
changes in the quality of life (QoL) asso-
ciated with acute and chronic pain man-
agement in Italy that involved patients af-
fected by chronic benign pain due to hip 
or knee OA, generalized OA, low back 
pain, a non-surgical hernia, slipped disc or 
shoulder periarthritis (13). The patients had 
experienced pain symptoms for at least six 
months before the start of the study. Various 
questionnaires were used to investigate the 
description of pain, healthcare use before 
and after enrolment, and the willingness to 
pay for therapy. The costs relating to acute 
pain (€ 57.00 in 2004), 30 days prior to the 
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clinical examination, concerned the Emer-
gency Department accesses and self-medi-
cations, and after the clinical examination 
they were incurred for diagnostic examina-
tions and drugs. As to the costs relating to 
chronic pain (€ 175.00 in 2005), there is no 
significant difference in expenditure before 
(diagnostic examinations) and after the ap-
pointment (mainly for therapy, the rest for 
diagnostic examinations). Pharmacologi-
cal prescriptions for acute pain included 
non-steroidal anti-inflammatory drugs 
(NSAIDs) (61%), opioids (40%), cortico-
steroids (17%), local anesthetics (1%), and 
other therapies in (24%) of the cases; and 
those for chronic pain included opioids 
(46%), local anesthetics (33%), cortico-
steroids (29%), NSAIDs 26%, and other 
therapies (45%). Another interesting find-
ing was that the QoL cost of an extremely 
high level of pain was between € 79.89 and 
€ 156.05, whereas in the case of moderate 
pain it was far higher, between € 515.21 
and € 843.06. 
RD-related pain is essentially chronic, and 
a paramount issue for public health policy 
makers.
n	 COSTS OF PAIN  
 IN RHEUMATOID ARTHRITIS
RA is a chronic disease characterized by 
progressive joint damage that causes dis-
ability, a worsening quality of life, and a re-
duced life expectancy, and affects 0.3-1.0% 
of the world’s population (about 300,000 
people in Italy); the male:female ratio is 
3-4:1. The comorbidities of RA are pain, 
fatigue and depression. RA affects patients 
of any age, including people who are still 
working. However, the progressive disabil-
ity it causes has a negative effect on work-
ing abilities and leads to lost work days and 
even unemployment. 
According to a recent study by the Scuola 
Superiore Sant’Anna, the annual average 
cost of 253,069 patients in Italy aged >18 
years is about € 3,388,593,910, of which 
€ 2,330,006,283 are direct costs (health 
costs € 698,976,578; non-health costs 
€ 1,631,029,705) and € 1,058,587,627 are 
indirect costs (14). Moreover, the total av-
erage annual cost per RA patient in Italy 
is € 13,390, 69% of which (€ 9207) is ac-
counted for by direct costs (health costs 
€ 2762; non-health costs € 6445, 48% of 
the total costs), and 31% (€ 4183) by in-
direct costs and lost productivity due to an 
annual average of 65 work days lost by pa-
tients and caregivers. The average annual 
cost of drugs per patient is € 2080, lead-
ing to a total amount of € 526,383,520, less 
than that due to lost productivity.
These findings confirm that the costs of RA 
(like those relating to other chronic RDs) 
are largely due to direct non-healthcare and 
indirect costs rather than direct healthcare 
costs. The authors concluded that, although 
it would increase direct healthcare costs, a 
greater use of biotechnological drugs could 
lead to a reduction in working disability 
and, consequently, direct non-healthcare 
and indirect costs. 
n	 COSTS OF PAIN  
 IN FIBROMYALGIA
Fibromyalgia (FM) is characterized by 
frequently incurable, chronic generalized 
pain that may be treated using analgesic 
drugs, NSAIDs, cyclooxygenase-2 inhibi-
tors (COXIBs), antidepressants, or anticon-
vulsants. Various studies of the costs of FM 
have been published (15). 
Knight et al. have recently studied the costs 
of 442 patients (385 women) in the USA, 
France and Germany, and confirmed that 
FM has much higher indirect costs than di-
rect costs (16).
 Another recent study by Sun et al. analyzed 
insurance databases to find the direct medi-
cal costs of 7871 patients with FM (89% 
female) who had a median age of 49 years 
at the start of drug treatment in 2008 (17): 
one group was taking duloxetine (3033), 
and a second pregabalin (4838). The costs 
in the two groups were: hospitalization 
$ 2994.9 vs $ 4949.6 (P<0.05), outpatient 
costs $ 8259.6 vs $ 10,312.2 (P<0.05), 
drug costs $ 5214.6 vs $ 5290.8 (P>0.05), 
and total physician costs $ 16,469.1 vs 
$ 20,552.6 (P<0.05).
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A previous study by the Italian Fibromy-
algia Network showed that a high degree 
of disability and the number of pathologies 
associated with FM could significantly in-
crease the direct and indirect costs of FM-
related pain management, whereas an early 
diagnosis reduced the use of economic re-
sources for drugs, medical appointments 
and diagnostic investigations (18). 
n	 COSTS OF THE DRUGS  
 USED FOR TREATING PAIN  
 IN RHEUMATIC DISEASES
The OsMeD report of AIFA (Italian Drug 
Agency, Agenzia Italiana del Farmaco) 
Use of drugs in Italy as of September 2012 
refers to the use of all types of drugs in 
hospitals. The cost for drugs used to treat 
patients with conditions affecting the mus-
culoskeletal system, which represent the 
eighth largest drug category in the public 
budget, amounted to € 442 million (7.3 
per capita). These costs are mainly asso-
ciated with the so-called therapeutic drug 
assistance (6.3 per capita), whereas the 
purchase of drugs by the public health fa-
cilities was much less significant (1.0 per 
capita). With respect to the national health-
care system, the expenditure for drugs to 
treat musculoskeletal disorders decreased 
by 9.0% against 2011. This decline is 
due to the combination of a reduction in 
consumption (-4.3%), in prices (-5.4%) 
and a positive mix effect (+0.5%). Data 
shows that the purchase of these drugs by 
healthcare facilities is substantially stable 
if compared with 2011 (+0.06%), while 
consumption by the general population is 
increasing (+6.6%). The most widely used 
drug categories by the national healthcare 
service were anti-inflammatory NSAIDs 
and COXIBs, followed by biphosponates. 
In terms of expenditure, biphosponates and 
COXIBs are the two most relevant catego-
ries. Biphosponates are also the category 
with the largest impact on the budgets of 
healthcare facilities. No active ingredient 
belonging to the musculoskeletal category 
is among the first 30 most widely used 
drugs in the national healthcare budget or 
direct distribution, and only the zolendron-
ic acid is in the list of hospital consump-
tion. 
Among the drugs for central nervous sys-
tem disorders, the list includes selective 
serotonin re-uptake inhibitors, other anti-
depressants and natural opioid alkcaloids, 
which are all frequently prescribed by 
rheumatologist for pain treatment. In par-
ticular, they are administered to treat FM or 
chronic arthritis when the CP is associated 
with a suspected central sensitization. The 
30 most widely used drugs also include: 
escitalopram (14th), levetiracetam (19th) 
pregabalin (24th), acetylsalicylic acid (25th) 
and duloxetine (26th). 
A recent Federfarma publication (April 
2013) on drug consumption in Italy report-
ed that musculoskeletal agents ranked 7th in 
terms of incidence on the healthcare budget 
in 2012 (19, 20). The group of anti-neoplas-
tic and immune-modulating drugs includes 
biotechnological drugs, but no mention is 
made of opioids or analgesic agents. Rheu-
matologic drugs were not among the most 
prescribed in 2012 nor among the first ten 
with the highest turnover in Italy. Vitamin 
D is included, but it is also prescribed by 
general practitioners and other specialists. 
According to a Farmindustria report, sales 
of musculoskeletal drugs in Italy in 2011 
accounted for 5.9% of total expenditure, 
which is less if compared with 24.9% for 
cardiovascular drugs, 15.1% for central 
nervous system drugs, and 14.7% for gas-
trointestinal drugs (21). 
The publication Pain proposal - Improv-
ing the Current and Future Management 
of Chronic Pain describes the results of a 
survey conducted in 15 European coun-
tries (including Italy) on the social impact 
of chronic pain. It addresses the following 
topics: Time to diagnosis in Europe (from 
not been diagnosed to 10 years or more), 
Average time to diagnosis (years), Time 
from diagnosis to adequate pain manage-
ment, Percentage still not diagnosed or 
not adequately managed, impact of pain 
on daily activities, and Average number of 
healthcare professional visits in the prior 
year. It concludes that a late diagnosis and 
an inadequate management of CP increase 
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global costs (visits, diagnostic examina-
tions, drugs, etc.), however Italy seems to 
be in a good position in terms of time to 
diagnosis. 
Indirect costs also include costs due to 
side effects. An observational study pre-
sented by J. Goldstein in San Diego on the 
occasion of the Digestive Disease Week 
made use of an administrative database 
of 15 million people, 97% of whom were 
covered by commercial insurance poli-
cies. The analysis involved 1800 patients 
(2/3 female) with an average of 60 years, 
who were prescribed NSAIDs for 90 days 
because of OA. During the following 12 
months, anemic patients were more likely 
to use healthcare resources (drugs, visits 
and diagnostic investigations) with an av-
erage cost of $ 42,368 against an average 
of $ 22,583 in a control group of patients 
who used NSAIDs but did not experience 
any significant change in hemoglobin lev-
els (P<0.0001) (22). 
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